Summit Trail Advisors’s Colgate-Palmolive CL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.83M Buy
68,417
+13,331
+24% +$1.19M 0.08% 137
2025
Q4
$4.35M Buy
55,086
+38,797
+238% +$3.04M 0.08% 155
2025
Q3
$1.3M Sell
16,289
-9,128
-36% -$779K 0.02% 680
2025
Q2
$2.31M Buy
+25,417
New +$2.32M 0.04% 234
2024
Q4
Sell
-8,629
Closed -$896K 466
2024
Q3
$896K Buy
8,629
+3,139
+57% +$320K 0.02% 282
2024
Q2
$533K Buy
5,490
+141
+3% +$13K 0.01% 361
2024
Q1
$482K Buy
5,349
+601
+13% +$50.9K 0.01% 346
2023
Q4
$378K Buy
4,748
+488
+11% +$36.7K 0.01% 334
2023
Q3
$303K Sell
4,260
-796
-16% -$59.5K 0.01% 373
2023
Q2
$390K Buy
+5,056
New +$391K 0.01% 316
2023
Q1
Sell
-2,902
Closed -$229K 401
2022
Q4
$229K Buy
+2,902
New +$218K 0.01% 338
2018
Q2
Sell
-3,634
Closed -$232K 518
2018
Q1
$232K Buy
3,634
+703
+24% +$50.6K 0.04% 342
2017
Q4
$224K Buy
+2,931
New +$214K 0.03% 389

Other funds holding CL

Summit Trail Advisors's CL Position: Q1 2026 in Review

Summit Trail Advisors increased its Colgate-Palmolive (CL) stake by 24% in Q1 2026, buying an estimated $1.19M and bringing the position to 68,417 shares worth $5.83M. The position accounts for 0.08% of the portfolio, ranked #137.

Summit Trail Advisors first reported a position in CL in Q4 2017 and has held it in 13 quarters since. 1,945 funds tracked by Wall St. Rank hold CL as of Q1 2026.

  • Summit Trail Advisors held 68,417 shares of Colgate-Palmolive worth $5.83M as of Q1 2026.
  • Summit Trail Advisors bought 13,331 Colgate-Palmolive shares in Q1 2026, an estimated $1.19M.
  • Colgate-Palmolive made up 0.08% of Summit Trail Advisors's portfolio in Q1 2026, its #137 holding.
  • Summit Trail Advisors first reported a position in Colgate-Palmolive in Q4 2017 and has held it in 13 quarters since.
  • 1,945 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.